Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15Business Wire • 06/08/22
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMABusiness Wire • 06/08/22
AbbVie's Failure Solidifies Vertex Pharmaceuticals' Cystic Fibrosis Leadership PositionSeeking Alpha • 06/06/22
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific SessionsBusiness Wire • 06/06/22
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) CongressBusiness Wire • 06/02/22
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual ConferenceBusiness Wire • 05/31/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTXPRNewsWire • 05/30/22
Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTXNewsfile Corp • 05/28/22
EQUITY ALERT: Rosen Law Firm Encourages Vertex Pharmaceuticals Incorporated Investors with Losses to Inquire About Class Action Investigation – VRTXBusiness Wire • 05/26/22
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic TherapiesBusiness Wire • 05/17/22
Vertex Announces $50 Million Commitment to Health Equity With Three Initial GrantsBusiness Wire • 05/17/22
Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull CaseSeeking Alpha • 05/06/22